Peptide Reports

IGF-1LR3

Community Protocol

IGF-1LR3

Preparation examples, syringe conversion, community-reported patterns and important limitations.

Educational and calculation-reference material only. Community reports are uncontrolled anecdotes and do not replace professional medical guidance, product labeling, or individualized clinical monitoring.

Scope

Preparation examples, syringe conversion, community-reported patterns and important limitations.

Available strengths: 1 MG

Preparation Examples

These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.

SetupDiluentConcentrationUnit conversion
1 MG vial – 2 mL exampleAdd 2 mL bacteriostatic water0.5 mg/mLEach U-100 unit = 5 mcg
1 MG vial – 1 mL exampleAdd 1 mL bacteriostatic water1 mg/mLEach U-100 unit = 10 mcg

Syringe Conversion

Reported amount1 MG setup1 MG setup
10 mcg2 units1 units
20 mcg4 units2 units
50 mcg10 units5 units
100 mcg20 units10 units

Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.

Community-Reported Patterns

Recurring reportFrequency seenContext in reports
10-20 mcgOnce dailyLower-start reports
20-50 mcgOnce dailyMost recurring range
50-100 mcgDaily in some reportsHigher experimental use

Observations

  • Community discussions most often centered on muscle growth, recovery and nutrient-partitioning goals.
  • The amount, frequency, route and cycle length varied substantially between reports.
  • Reported outcomes were commonly confounded by diet, training, other products or existing treatment.

Caveats

  • IGF-1 activity can cause hypoglycemia and may promote unwanted tissue growth; unsupervised exposure is high risk.
  • Community reports are uncontrolled anecdotes and do not establish an appropriate dose, safety, product identity, purity or efficacy.

Sources

  1. Community search: IGF-1LR3
  2. PubMed literature search: IGF-1LR3